✦ LIBER ✦

Treatment effect modifiers for the patient education programme for Parkinson’s disease

✍ Scribed by L. E. I. A’Campo; E. M. Wekking; N. G. A. Spliethoff-Kamminga; T. Stijnen; R. A. C. Roos

Book ID: 111309716
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 119 KB
Volume: 66
Category: Article
ISSN: 1368-5031
DOI: 10.1111/j.1742-1241.2011.02791.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An evaluation of the patient education p

An evaluation of the patient education programme for Parkinson’s disease in clinical practice

✍ L. E. I. A’Campo; N. G. A. Spliethoff-Kamminga; R. A. C. Roos 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB

A controlled trial of an educational pro

A controlled trial of an educational programme for people with Parkinson's disease

✍ Susanne Lindskov; Albert Westergren; Peter Hagell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Istradefylline for the treatment of Park

Istradefylline for the treatment of Parkinson's disease

✍ Park, Ariane; Stacy, Mark 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 190 KB

Pramipexole for the treatment of early P

Pramipexole for the treatment of early Parkinson’s disease

✍ Perez-Lloret, Santiago; Rey, María Verónica; Ratti, Luca; Rascol, Olivier 📂 Article 📅 2011 🏛 Expert Reviews 🌐 English ⚖ 824 KB

Rivastigmine for the treatment of Parkin

Rivastigmine for the treatment of Parkinson’s disease dementia

✍ Aarsland, Dag; Ehrt, Uwe; Gauthier, Serge 📂 Article 📅 2010 🏛 Future Medicine 🌐 English ⚖ 486 KB

A novel sublingual apomorphine treatment

A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease

✍ William Ondo; Christine Hunter; Michael Almaguer; Joseph Jankovic 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 2 views

We tested a novel preparation of a sublingual apomorphine hydrochloride tablet (APO) in 10 patients with advanced Parkinson's disease complicated by motor fluctuations. After a dose titration, patients took either 40 mg APO three times per day alternating with levodopa doses (eight patients) or six